CanSino Biologics' (HKG:6185, SHA:688185) new drug application for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine was accepted by China's National Medical Products Administration, according to an Aug. 16 Hong Kong bourse filing.
Shares of the vaccine maker were up 2% in Monday afternoon trading.
The product is a booster vaccine for diphtheria, tetanus, and acellular pertussis for adolescents and adults aged six years and above.